Bayer agrees to help make CureVac’s COVID-19 vaccine
FILE PHOTO: A bridge is decorated with the logo of Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay
BERLIN — German pharmaceutical giant Bayer said Monday it will help CureVac produce its experimental Covid-19 vaccine, the latest drugmaker to offer up manufacturing capacity as supplies fall behind demand.
Bayer said it expects to produce 161 million doses of CureVac’s experimental vaccine, which is currently in late-stage testing, in 2022, its head of pharma Stefan Oelrich told a news conference.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
